IXICO plc New contract in progressive supranuclear palsy (2557D)

TIDMIXI

RNS Number : 2557D

IXICO plc

30 January 2018

30 January 2018

IXICO plc

("IXICO" or the "Company")

New $2.7m contract in progressive supranuclear palsy with a global pharmaceutical company

IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today announces that it has signed an additional new contract with an existing global pharmaceutical customer. The contract value is $2.7m, over a seven year term, to commence immediately.

IXICO will provide its technology enabled imaging services in a clinical trial of a novel therapeutic to treat people with progressive supranuclear palsy ('PSP'), a rare neurodegenerative disease.

PSP is caused by the premature loss of nerve cells in certain parts of the brain, which leads to difficulties with balance, movement, vision, speech and swallowing. This new contract is IXICO's third clinical trial project in PSP and follows contracts announced in October 2016 and March 2017 with values of $1.2m and $1.5m respectively. These contracts, together with two new Huntington's disease contracts announced in September 2017, demonstrate the depth and breadth of IXICO's capabilities and expert knowledge, as it continues to win novel neurodegenerative disease projects.

As part of the study, IXICO will use its TrialTracker(TM) digital platform and image analysis algorithms to collect and analyse MRI data from specialist imaging centres across Europe, North America and Australasia. This data will be used to evaluate the safety and efficacy of this novel treatment.

Giulio Cerroni, CEO of IXICO, said: "This additional, new contract in PSP from an existing customer indicates the value our customers see in IXICO's extensive neurological disease expertise combined with our proprietary digital technologies. Through our proven ability to collect and analyse clinical data in a standardized and regulatory-complaint format, we continue to build on our successful track record as a partner of choice to the biopharmaceutical industry".

For further information please contact:

 
 IXICO plc 
  Giulio Cerroni, Chief Executive            Tel: +44 20 
  Officer                                    3763 7499 
  Susan Lowther, Chief Financial Officer 
 
 Shore Capital (Nomad and Broker)          Tel: +44 20 
  Edward Mansfield /Anita Ghanekar          7408 4090 
 
 FTI Consulting Limited (Investor          Tel: +44 20 
  Relations)                                3727 1000 
  Simon Conway/Mo Noonan 
 

About IXICO

IXICO is the digital technologies company serving neuroscience. Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global pharmaceutical industry to select participants for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance. Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable sponsors to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes.

More information is available on www.IXICO.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

CNTDKLFLVFFFBBZ

(END) Dow Jones Newswires

January 30, 2018 02:00 ET (07:00 GMT)